Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2662)	5/13/2010 1:46:55 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

IMMU is up 6.93% as it is still tryin to stay above the resistance at the $4 level<g> Volume of 2.27M is about 2.5x its ADV bigcharts.marketwatch.com IMMU announced today some posters and one published abstract that it will be presenting at the European Rheumatology Congress in Rome,Italy, in June . It plans to report some results on epratuzumab, its anti-CD22 humanized monoclonal antibody licensed to UCB for autoimmune disease indications, from the PIIb study in patients with LE. In the second half of 2010, UCB will be starting two PIIIs of epratuzumab in patients with moderate and severe LE. The stock needs to close above $4 before it can retest the Jan21 at $4.94 bigcharts.marketwatch.com Although the results on the 2ndQ were not good, the results of the 3rdQ showed a 29% improvement on revenues and a 400% improvement on earnings.<g> Since IMMU also had good results on the 1stQ, the earnings for 2010 are expected at $0.36 vs. $0.03 in 2009 The ACTAY is $6.50 and it seems that with some good news the stock could get to the $7 level in spite of the fact that the "analysts" are expecting for IMMU to report again on the red in 2011.<g> bigcharts.marketwatch.com Bernard